JP2016508969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508969A5 JP2016508969A5 JP2015548050A JP2015548050A JP2016508969A5 JP 2016508969 A5 JP2016508969 A5 JP 2016508969A5 JP 2015548050 A JP2015548050 A JP 2015548050A JP 2015548050 A JP2015548050 A JP 2015548050A JP 2016508969 A5 JP2016508969 A5 JP 2016508969A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- alkyl
- patent document
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 201000011510 cancer Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 206010020243 Hodgkin's disease Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000005962 mycosis fungoide Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 208000006617 Islet Cell Carcinoma Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 230000001058 adult Effects 0.000 claims 2
- 201000009614 adult lymphoma Diseases 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100004131 CNKSR1 Human genes 0.000 claims 1
- 101710034357 CNKSR1 Proteins 0.000 claims 1
- 208000002458 Carcinoid Tumor Diseases 0.000 claims 1
- 206010007275 Carcinoid tumour Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 208000006178 Malignant Mesothelioma Diseases 0.000 claims 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 1
- 206010028729 Nasal cavity cancer Diseases 0.000 claims 1
- 206010028767 Nasal sinus cancer Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 201000006984 Sezary's disease Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 206010046885 Vaginal cancer Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 101700061999 nhr-3 Proteins 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 claims 1
- 201000007052 paranasal sinus cancer Diseases 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000009365 thymic carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 101700006234 AKT1 Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 102100001248 AKT1 Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102100009279 KRAS Human genes 0.000 description 4
- 101710033922 KRAS Proteins 0.000 description 4
- -1 Phosphatidylinositol Ether Lipid Chemical class 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000003197 protein kinase b inhibitor Substances 0.000 description 3
- 101710033925 HRAS Proteins 0.000 description 2
- 102100009283 HRAS Human genes 0.000 description 2
- 101710033916 NRAS Proteins 0.000 description 2
- 102100001119 NRAS Human genes 0.000 description 2
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 2
- 108020004532 RAS Proteins 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000576 supplementary Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 description 1
- 101700006583 AKT2 Proteins 0.000 description 1
- LBNUURWIDGNVSU-UHFFFAOYSA-N CCCN(C(CN1C)=O)C1=O Chemical compound CCCN(C(CN1C)=O)C1=O LBNUURWIDGNVSU-UHFFFAOYSA-N 0.000 description 1
- WFLQKGQIUPCFDB-UHFFFAOYSA-N CCCN(C(CO1)=O)C1=O Chemical compound CCCN(C(CO1)=O)C1=O WFLQKGQIUPCFDB-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 101700011770 PDK1 Proteins 0.000 description 1
- 108060006638 PDPK1 Proteins 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N Perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 Perifosine Drugs 0.000 description 1
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- RQQIRMLGKSPXSE-UQPICLANSA-N Phosphatidylinositol-3,4,5-trisphosphate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-UQPICLANSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 108050001185 Pleckstrin homology domain Proteins 0.000 description 1
- 102000010995 Pleckstrin homology domain Human genes 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- GWIKYPMLNBTJHR-UHFFFAOYSA-M thiosulfonate group Chemical group S(=S)(=O)[O-] GWIKYPMLNBTJHR-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Description
RAS遺伝子(KRAS、HRAS、及びNRAS)のうちの少なくとも1つの単一点突然変異は、多くのヒトの癌において、とくに結腸、肺、及び膵臓癌において見られる。RAS突然変異は、KRASにおいて最も一般的に(約85%)、NRASにおいてはより低い頻度で(約12%)、またHRASにおいては稀に(3%)見られる。KRASは2つのスプライスバリアントA及びBをコードし、エクソン4の代替的利用に起因する異なるC末端配列を伴う。変異型KRAS(mut−KRAS)は、全てのヒト腫瘍の最大約25%に存在しうる。mut−KRASは、腫瘍の成長及び治療に対する耐性を推進するにあたり重要な役割を果たしうる。mut−KRAS活性に対して穏やかな効果しか有さない薬剤でさえ、またはmut−KRASのサブセットの選択的阻害を示す薬剤は、治療に重要な影響を有し、また苦しむ癌患者及び罹患率を低下させうる。従って、mut−KRAS腫瘍の成長を阻害する新しい薬剤の発見が望ましい。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 国際公開第2003/076436号
(特許文献2) 国際公開第2003/084473号
(特許文献3) 国際公開第2005/000862号
(特許文献4) 国際公開第2005/005421号
(特許文献5) 国際公開第2005/090461号
(特許文献6) 国際公開第2005/097758号
(特許文献7) 国際公開第2006/046914号
(特許文献8) 国際公開第2007/039173号
(特許文献9) 国際公開第2008/083158号
(特許文献10) 国際公開第2009/129267号
(特許文献11) 国際公開第2010/085968号
(特許文献12) 国際公開第2011/032169号
(特許文献13) 国際公開第2014/093988号
(特許文献14) 国際公開第2016/172191号
(特許文献15) 米国特許第4,939,140号明細書
(特許文献16) 米国特許第4,251,528号明細書
(特許文献17) 米国特許第6,924,284号明細書
(特許文献18) 米国特許出願公開第2011/0144066号明細書
(特許文献19) 米国特許第6,066,311号明細書
(特許文献20) 米国特許出願公開第2012/0189670号明細書
(非特許文献)
(非特許文献1) ANWAR et al."Reactions of some 5−aryl−2−thiono−1,3,4−thiadia−zoles"January 1,1981,Romanian Journal of Chemistry 26(8):1127−1134
(非特許文献2) BANKER et al."Modern Pharmaceutics"1979,Marcel Dekker,Inc.,New York(TOC).
(非特許文献3) CARPTEN et al."A Transforming Mutation in the Pleckstrin Homology Domain of AKT1 in Cancer"July 26,2007,Nature 448(7152):439−444
(非特許文献4) CASTILLO et al."Preferential Inhibition of Akt and Killing of Akt−dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues"April 15,2004,Cancer Res.64(8):2782−92
(非特許文献5) CATLEY et al."Alkyl Phospholipids Perifosine Induces Myeloid Hyperplasia in a Murin Myeloma Model"July 2007,Exp.Hematol.35(7):1038−1046(abstract)
(非特許文献6) Chemical Abstract Database compound(CAS RN 1022250−16−3)entering date May 25,2008
(非特許文献7) Chemical Abstract Database compound(CAS RN 1022557−01−2)entering date May 26,2008
(非特許文献8) Chemical Abstract Database: compound(CAS RN 477482−99−8),entering date December 12,2002
(非特許文献9) Chemical Abstract Database: compound (CAS RN 477483−04−8),entering date December 12,2002
(非特許文献10) Chemical Abstract Database: compound(CAS RN 919458−54−1),entering date February 6,2007
(非特許文献11) Database Pubchem(Online)NCBI: September 11,2005 Database accession no. CID3800302
(非特許文献12) Database Pubchem(Online)NCBI: September 7,2005 Database accession no.CID3268165
(非特許文献13) Database Pubchem(Online)NCBI; February 29,2008 Database accession no.CID24283805
(非特許文献14) European Search Report and Written Opinion dated February 2,2012 for EP 11181871
(非特許文献15) FELDMAN et al."Novel Small Molecule Inhibitors of 3’−phosphoinositide−dependent Kinsase1(PDK−1)"September 30,2004,Eur.J.Cancer Supp.2(249):77
(非特許文献16) FENGL "Enteric Coating" October 22, 2002, Enerex.ca 5 pages
(非特許文献17) GILLS et al."Spectrum of Activity and Molecular Correlates of Response to Phosphatidylinositol Ether Lipid Analogues, Novel Lipid−based Inhibitors of Akt"March 2006,Mol.Cancer Ther.5(3):713−722
(非特許文献18) GIRANDA et al."Novel ATP−competitive AKT Inhibitors Slow the Progression of Tumors in vivo"September 30,2004,Eur.J.Cancer Supp.2(246):76−77
(非特許文献19) GOODMAN et al."The Pharmaceutical Basis of Therapeutics,6th ed." 1980,MacMillan Publishing Co.,New York(TOC).
(非特許文献20) HUMPHREYS et al."Toxicity and antileukemic effectiveness of pyridine derivatives and 1,3,4−thiadiazole derivatives in mice.Relationship to nicotinamide antagonism"1962,Cancer Res.22:483−550
(非特許文献21) International Search Report and Written Opinion dated June 3,2014 for PCT/US2013/75505
(非特許文献22) International Search Report and Written Opinion dated May 26,2011 for PCT/US2010/048813
(非特許文献23) International Search Report and Written Opinion dated October 19,2009 for PCT/US2009/040575
(非特許文献24) International Search Report dated December 15,2009 for PCT/US2009/040575
(非特許文献25) International Search Report dated July 29,2016 for PCT/US2016/028414
(非特許文献26) KIM et al."Targeting the Phosphatidylinositol−3 Kinase/Akt Pathway for the Treatment of Cancer"December 2005,Curr.Opin.Investig.Drugs 6(12):1250−1258
(非特許文献27) KOMANDER et al."Structural Insights into the Regulation of Pdk1 by Phosphoinositides and Inositol Phosphates" 2004,EMBO J.23(20):3918−3928
(非特許文献28) KUMAR et al."AKT Crystal Structure and AKT−specific Inhibitors"November 2005,Oncogene 24(50):7493−7501
(非特許文献29) LI "Recent Progress in the Discovery of Akt Inhibitors as Anticancer Agents"2007,Expert Opin.Ther.Patents 17:1077−1130
(非特許文献30) MAHADEVAN et al. "Discovery of a novel class of AKT pleckstrin homology domain inhibitors" September 2008, Mol. Cancer Ther. 7(9):2621−2632
(非特許文献31) MAHIEU et al. "Synthesis of new thiosulfonates and disulfides from sulfonyl chlorides and thiols" January 1, 1986, Synthetic Communications 16(13):1709−1722
(非特許文献32) MEUILLET et al."In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX−316"2004,Oncol.Res.14(10):513−527(abstract)
(非特許文献33) MEUILLET et al."Specific Inhibition of the Akt2 Pleckstrin Homology domain by D−3−deoxy−phosphatidyl−myo−inositol Analogues"April 2003,Mol.Cancer.Ther.2(4):390−399
(非特許文献34) MILBURN et al."Binding of Phosphatidylinositol 3,4,5−trisphosphate to the Pleckstrin Homology Domain of Protein Kinase B Induces a Conformational Change"2003,Biochem.J.375:531−538
(非特許文献35) MIYAHARA et al."Antitumor activity of 2−Acylamino−1,3,4−thiadiazoles and related compounds"1982,Chem.Pharm.Bul.30(12):4402−4406
(非特許文献36) MOSES,et al.,"In vitro and in vivo activity of novel small−molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT"June 15,2009,Cancer Research 69(12):5073−5081
(非特許文献37) Office Action issued in Australian Application No.2009236256,mailed May 2,2013
(非特許文献38) Office Action issued in Australian Application No.2009236256,mailed June 11,2014
(非特許文献39) Office Action issued in European Application No.11181871.2,mailed July 10,2013
(非特許文献40) Office Action issued in European Application No.11181871.2,mailed September 25,2014
(非特許文献41) Office Action issued in U.S.Application No.12/937,898,mailed August 30,2012
(非特許文献42) Office Action issued in U.S.Application No.12/937,898,mailed June 18,2012
(非特許文献43) Office Action issued in U.S.Application No.13/789,209 dated June 25,2014
(非特許文献44) PENG et al."Dwarfism,Impaired Skin Development,Skeletal Muscle Atrophy,Delayed Bone Development,and Impeded Adipogenesis in Mice Lacking Akt1 and Akt2"June 1,2003,Genes Dev.17(11):1352−1365
(非特許文献45) POWELL et al."Bile Acid Hydrophobicity is Correlated with Induction of Apoptosis and/or Growth Arrest in HCT116 Cells"2001,Biochem J.356:481−486
(非特許文献46) RUNGE et al."Uber einige unsymmetrishce heterocyclische Disulfide,II"July 1,1963,J.Fuer Praktische Chemie 21(1−2):39−49(cited in German/ no translation available)
(非特許文献47) SASSIVER et al."2−Sulfanilamido−5−methoxy−,1,3,4−thiadiazole and related compounds"1966,J.Med.Chem.9(4):541−545
(非特許文献48) STEIN et al."Discovery and structure of activity relationships of sulfonamide ETA−selective antagonists"1995,J.Med.Chem.38:1344−1354
(非特許文献49) Supplementary European Search Report and Written Opinion dated September 17,2012 for EP 10816289
(非特許文献50) Supplementary European Search Report and Written Opinion dated April 14,2016 for EP13863280
(非特許文献51) THOMAS et al."High−resolution Structure of Pleckstrin Homology Domain of Protein Kinase B/akt Bound to Phosphatidylinositol(3,4,5)−trisphosphate"July 2002,Curr.Biol.12(14):1256−1262
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 国際公開第2003/076436号
(特許文献2) 国際公開第2003/084473号
(特許文献3) 国際公開第2005/000862号
(特許文献4) 国際公開第2005/005421号
(特許文献5) 国際公開第2005/090461号
(特許文献6) 国際公開第2005/097758号
(特許文献7) 国際公開第2006/046914号
(特許文献8) 国際公開第2007/039173号
(特許文献9) 国際公開第2008/083158号
(特許文献10) 国際公開第2009/129267号
(特許文献11) 国際公開第2010/085968号
(特許文献12) 国際公開第2011/032169号
(特許文献13) 国際公開第2014/093988号
(特許文献14) 国際公開第2016/172191号
(特許文献15) 米国特許第4,939,140号明細書
(特許文献16) 米国特許第4,251,528号明細書
(特許文献17) 米国特許第6,924,284号明細書
(特許文献18) 米国特許出願公開第2011/0144066号明細書
(特許文献19) 米国特許第6,066,311号明細書
(特許文献20) 米国特許出願公開第2012/0189670号明細書
(非特許文献)
(非特許文献1) ANWAR et al."Reactions of some 5−aryl−2−thiono−1,3,4−thiadia−zoles"January 1,1981,Romanian Journal of Chemistry 26(8):1127−1134
(非特許文献2) BANKER et al."Modern Pharmaceutics"1979,Marcel Dekker,Inc.,New York(TOC).
(非特許文献3) CARPTEN et al."A Transforming Mutation in the Pleckstrin Homology Domain of AKT1 in Cancer"July 26,2007,Nature 448(7152):439−444
(非特許文献4) CASTILLO et al."Preferential Inhibition of Akt and Killing of Akt−dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues"April 15,2004,Cancer Res.64(8):2782−92
(非特許文献5) CATLEY et al."Alkyl Phospholipids Perifosine Induces Myeloid Hyperplasia in a Murin Myeloma Model"July 2007,Exp.Hematol.35(7):1038−1046(abstract)
(非特許文献6) Chemical Abstract Database compound(CAS RN 1022250−16−3)entering date May 25,2008
(非特許文献7) Chemical Abstract Database compound(CAS RN 1022557−01−2)entering date May 26,2008
(非特許文献8) Chemical Abstract Database: compound(CAS RN 477482−99−8),entering date December 12,2002
(非特許文献9) Chemical Abstract Database: compound (CAS RN 477483−04−8),entering date December 12,2002
(非特許文献10) Chemical Abstract Database: compound(CAS RN 919458−54−1),entering date February 6,2007
(非特許文献11) Database Pubchem(Online)NCBI: September 11,2005 Database accession no. CID3800302
(非特許文献12) Database Pubchem(Online)NCBI: September 7,2005 Database accession no.CID3268165
(非特許文献13) Database Pubchem(Online)NCBI; February 29,2008 Database accession no.CID24283805
(非特許文献14) European Search Report and Written Opinion dated February 2,2012 for EP 11181871
(非特許文献15) FELDMAN et al."Novel Small Molecule Inhibitors of 3’−phosphoinositide−dependent Kinsase1(PDK−1)"September 30,2004,Eur.J.Cancer Supp.2(249):77
(非特許文献16) FENGL "Enteric Coating" October 22, 2002, Enerex.ca 5 pages
(非特許文献17) GILLS et al."Spectrum of Activity and Molecular Correlates of Response to Phosphatidylinositol Ether Lipid Analogues, Novel Lipid−based Inhibitors of Akt"March 2006,Mol.Cancer Ther.5(3):713−722
(非特許文献18) GIRANDA et al."Novel ATP−competitive AKT Inhibitors Slow the Progression of Tumors in vivo"September 30,2004,Eur.J.Cancer Supp.2(246):76−77
(非特許文献19) GOODMAN et al."The Pharmaceutical Basis of Therapeutics,6th ed." 1980,MacMillan Publishing Co.,New York(TOC).
(非特許文献20) HUMPHREYS et al."Toxicity and antileukemic effectiveness of pyridine derivatives and 1,3,4−thiadiazole derivatives in mice.Relationship to nicotinamide antagonism"1962,Cancer Res.22:483−550
(非特許文献21) International Search Report and Written Opinion dated June 3,2014 for PCT/US2013/75505
(非特許文献22) International Search Report and Written Opinion dated May 26,2011 for PCT/US2010/048813
(非特許文献23) International Search Report and Written Opinion dated October 19,2009 for PCT/US2009/040575
(非特許文献24) International Search Report dated December 15,2009 for PCT/US2009/040575
(非特許文献25) International Search Report dated July 29,2016 for PCT/US2016/028414
(非特許文献26) KIM et al."Targeting the Phosphatidylinositol−3 Kinase/Akt Pathway for the Treatment of Cancer"December 2005,Curr.Opin.Investig.Drugs 6(12):1250−1258
(非特許文献27) KOMANDER et al."Structural Insights into the Regulation of Pdk1 by Phosphoinositides and Inositol Phosphates" 2004,EMBO J.23(20):3918−3928
(非特許文献28) KUMAR et al."AKT Crystal Structure and AKT−specific Inhibitors"November 2005,Oncogene 24(50):7493−7501
(非特許文献29) LI "Recent Progress in the Discovery of Akt Inhibitors as Anticancer Agents"2007,Expert Opin.Ther.Patents 17:1077−1130
(非特許文献30) MAHADEVAN et al. "Discovery of a novel class of AKT pleckstrin homology domain inhibitors" September 2008, Mol. Cancer Ther. 7(9):2621−2632
(非特許文献31) MAHIEU et al. "Synthesis of new thiosulfonates and disulfides from sulfonyl chlorides and thiols" January 1, 1986, Synthetic Communications 16(13):1709−1722
(非特許文献32) MEUILLET et al."In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX−316"2004,Oncol.Res.14(10):513−527(abstract)
(非特許文献33) MEUILLET et al."Specific Inhibition of the Akt2 Pleckstrin Homology domain by D−3−deoxy−phosphatidyl−myo−inositol Analogues"April 2003,Mol.Cancer.Ther.2(4):390−399
(非特許文献34) MILBURN et al."Binding of Phosphatidylinositol 3,4,5−trisphosphate to the Pleckstrin Homology Domain of Protein Kinase B Induces a Conformational Change"2003,Biochem.J.375:531−538
(非特許文献35) MIYAHARA et al."Antitumor activity of 2−Acylamino−1,3,4−thiadiazoles and related compounds"1982,Chem.Pharm.Bul.30(12):4402−4406
(非特許文献36) MOSES,et al.,"In vitro and in vivo activity of novel small−molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT"June 15,2009,Cancer Research 69(12):5073−5081
(非特許文献37) Office Action issued in Australian Application No.2009236256,mailed May 2,2013
(非特許文献38) Office Action issued in Australian Application No.2009236256,mailed June 11,2014
(非特許文献39) Office Action issued in European Application No.11181871.2,mailed July 10,2013
(非特許文献40) Office Action issued in European Application No.11181871.2,mailed September 25,2014
(非特許文献41) Office Action issued in U.S.Application No.12/937,898,mailed August 30,2012
(非特許文献42) Office Action issued in U.S.Application No.12/937,898,mailed June 18,2012
(非特許文献43) Office Action issued in U.S.Application No.13/789,209 dated June 25,2014
(非特許文献44) PENG et al."Dwarfism,Impaired Skin Development,Skeletal Muscle Atrophy,Delayed Bone Development,and Impeded Adipogenesis in Mice Lacking Akt1 and Akt2"June 1,2003,Genes Dev.17(11):1352−1365
(非特許文献45) POWELL et al."Bile Acid Hydrophobicity is Correlated with Induction of Apoptosis and/or Growth Arrest in HCT116 Cells"2001,Biochem J.356:481−486
(非特許文献46) RUNGE et al."Uber einige unsymmetrishce heterocyclische Disulfide,II"July 1,1963,J.Fuer Praktische Chemie 21(1−2):39−49(cited in German/ no translation available)
(非特許文献47) SASSIVER et al."2−Sulfanilamido−5−methoxy−,1,3,4−thiadiazole and related compounds"1966,J.Med.Chem.9(4):541−545
(非特許文献48) STEIN et al."Discovery and structure of activity relationships of sulfonamide ETA−selective antagonists"1995,J.Med.Chem.38:1344−1354
(非特許文献49) Supplementary European Search Report and Written Opinion dated September 17,2012 for EP 10816289
(非特許文献50) Supplementary European Search Report and Written Opinion dated April 14,2016 for EP13863280
(非特許文献51) THOMAS et al."High−resolution Structure of Pleckstrin Homology Domain of Protein Kinase B/akt Bound to Phosphatidylinositol(3,4,5)−trisphosphate"July 2002,Curr.Biol.12(14):1256−1262
Claims (34)
- 式IAの化合物、またはそれらの薬学的に許容可能な塩であって、
Rが、−C1−C4アルキル、−NO2、−NH2、−NHSO2CH3、−C1−C5シクロアルキル、もしくは−CF3であり、
R2がHであり、またはR及びR2が
R1が、−C(O)、−C(O)O(C1−C4アルキル)、−C(O)OH、−C1−C4アルキル−OH、−CH(OH)(CH2)nNH2、−CH(OH)、−C(OH)CNO2、−(CH2)nNO2、−CHO、−C(O)NHR3、
nは、1、2、3、もしくは4であり、
R3は、−C1−C4アルキル、−C1−C2アルキル−C(O)NH2、もしくは−S(O)2CH3であり、
RがMeの場合はR1が−C(O)OCH2CH3ではない、
化合物、またはそれらの薬学的に許容可能な塩。 - 請求項1記載の化合物において、R1が−C(O)O(C1−C4アルキル)である、化合物。
- 請求項1記載の化合物において、R1が−−C1−C4アルキル−OHである、化合物。
- 請求項1記載の化合物において、R1が−C(O)NHR3である、化合物。
- 請求項1記載の化合物において、Rがメチルである、化合物。
- 請求項1記載の化合物において、Rが−C1−C5シクロアルキルである、化合物。
- 請求項10記載の化合物において、R4がメチルである、化合物。
- 請求項10記載の化合物において、R5が−C2−C6アルケニル−OHもしくは−C2−C6アルケニル−C(O)−C1−C4アルキルである、化合物。
- 請求項14記載の化合物において、R8がシクロプロピルもしくはシクロブチルである、化合物。
- 請求項10記載の化合物において、R7がHである、化合物。
- 請求項20記載の化合物において、R9がメチルである、化合物。
- 請求項20記載の化合物において、R10が−C(O)OC1−C4アルキルである、
化合物。 - 請求項22記載の化合物において、C1−C4アルキルがエチルである、化合物。
- 請求項28記載の化合物において、R13がメチルである、化合物。
- 請求項28記載の化合物において、R14がメチルである、化合物。
- 癌を治療する方法であって、有効量の請求項1〜31記載の化合物を投与する工程を有する、方法。
- 請求項32記載の方法において、前記癌が、副腎皮質癌腫、肛門癌、膀胱癌、脳腫瘍、乳癌、カルチノイド腫瘍、胃腸癌、原発腫瘍が不明の癌腫、子宮頸癌、結腸癌、子宮内膜癌、食道癌、肝外胆管癌、ユーイング腫瘍(PNET)、頭蓋外胚細胞腫瘍、眼の癌、眼内黒色腫、胆嚢癌、胃癌(胃)、胚細胞腫瘍、性腺外腫瘍、妊娠性絨毛腫瘍、頭頸部癌、下咽頭癌、島細胞癌腫、腎臓癌、喉頭癌、白血病、成人急性リンパ芽球性白血病、小児急性リンパ芽球性白血病、舌及び口腔癌、肝臓癌、肺癌、リンパ腫、AIDS関連リンパ腫、中枢神経系(原発)リンパ腫、皮膚T細胞リンパ腫、ホジキン病、成人リンパ腫、ホジキン病、小児リンパ腫、非ホジキン病、成人リンパ腫、非ホジキン病、小児、悪性中皮腫、黒色腫、メルケル細胞癌腫、原発腫瘍不明の転移性扁平頸部癌、多発性骨髄腫及び他の形質細胞腫瘍、菌状息肉症、骨髄異形成症候群、骨髄増殖性障害、上咽頭癌、神経芽細胞種、口腔癌、中咽頭癌、骨肉腫、上皮性卵巣癌、卵巣胚細胞腫瘍、膵臓癌、外分泌系膵臓癌、島細胞癌腫、副鼻腔及び鼻腔癌、副甲状腺癌、陰茎癌、脳下垂体癌、形質細胞腫瘍、前立腺癌、横紋筋肉腫、小児、直腸癌、腎細胞癌、腎盂尿管癌、移行上皮癌、唾液腺癌、セザリー症候群、皮膚癌、皮膚癌、皮膚T細胞リンパ腫、皮膚癌、カポジ肉腫、皮膚癌、黒色腫、小腸癌、軟部肉腫、成人軟部肉腫、小児、胃癌、精巣癌、胸腺腫、悪性、甲状腺癌、尿道癌、子宮癌、肉腫、稀な小児癌、膣癌、外陰癌、ウィルムス腫瘍、並びにこれらの組み合わせから選択されるものである、方法。
- CNKSR1を阻害する方法であって、有効量の請求項1〜31記載の化合物を投与する工程を有する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737658P | 2012-12-14 | 2012-12-14 | |
US61/737,658 | 2012-12-14 | ||
PCT/US2013/075505 WO2014093988A2 (en) | 2012-12-14 | 2013-12-16 | Methods and compositions for inhibiting cnksr1 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016508969A JP2016508969A (ja) | 2016-03-24 |
JP2016508969A5 true JP2016508969A5 (ja) | 2017-02-23 |
JP6357292B2 JP6357292B2 (ja) | 2018-07-11 |
Family
ID=50935099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015548050A Active JP6357292B2 (ja) | 2012-12-14 | 2013-12-16 | Cnksr1を阻害するための方法及び組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9340532B2 (ja) |
EP (1) | EP2931280B1 (ja) |
JP (1) | JP6357292B2 (ja) |
AU (1) | AU2013358876B2 (ja) |
CA (1) | CA2895162C (ja) |
MX (1) | MX2015007608A (ja) |
WO (1) | WO2014093988A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2895162C (en) | 2012-12-14 | 2021-03-09 | D. Lynn Kirkpatrick | Methods and compositions for inhibiting cnksr1 |
WO2016172191A1 (en) * | 2015-04-20 | 2016-10-27 | Phusis Therapeutics, Inc. | Compounds, compositions and methods for inhibiting cnksr1 |
WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
CN110698411B (zh) * | 2018-07-09 | 2023-05-09 | 四川大学 | 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途 |
WO2022187804A1 (en) * | 2021-03-02 | 2022-09-09 | Icahn School Of Medicine At Mount Sinai | Benzoxazolone inhibitors of inflammasomes |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA775563A (en) | 1968-01-09 | Frank W. Horner Limited | Hypoglycemic thiadiazoles | |
GB828963A (en) | 1956-08-03 | 1960-02-24 | Rhone Poulenc Sa | Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole |
US3821222A (en) | 1971-11-22 | 1974-06-28 | Chevron Res | Hydrocarbyl sulfenylmercapto pyrimidines |
US4017489A (en) | 1975-07-10 | 1977-04-12 | The Goodyear Tire & Rubber Company | Process of preparing unsymmetrical disulfides |
DE2556011A1 (de) | 1975-12-12 | 1977-06-23 | Merck Patent Gmbh | Disulfide |
IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
GB2152497B (en) | 1983-11-28 | 1987-08-05 | Otsuka Kagaku Kk | Process for the preparation of azetidinone derivatives |
FR2573077B1 (fr) | 1984-11-13 | 1987-02-13 | Sanofi Sa | Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant |
US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
US4990523A (en) | 1989-06-19 | 1991-02-05 | A. H. Robins Company, Incorporated | Treatment of chronic inflammatory joint disease with arylsulfonamides |
GB9507415D0 (en) | 1994-06-08 | 1995-05-31 | Zylepsis Ltd | Production and uses of caffeic acid and derivatives thereof |
US6139875A (en) | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
FR2815032B1 (fr) | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
WO2002083064A2 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | A method of treating cancer |
JP2005501848A (ja) * | 2001-08-15 | 2005-01-20 | アイコス コーポレイション | 2h−フタラジン−1−オンおよびその使用方法 |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003226301A1 (en) | 2002-04-08 | 2003-10-20 | Merck And Co., Inc. | Method of treating cancer |
GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
EA011299B1 (ru) | 2003-06-24 | 2009-02-27 | Айсис Инновейшен Лимитед | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах |
CA2531418A1 (en) | 2003-07-08 | 2005-01-20 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
EP1751225B1 (en) | 2004-03-19 | 2009-08-05 | The Tapemark Company | Thermoplastic films and methods for making |
JP2007530589A (ja) | 2004-03-26 | 2007-11-01 | アンフォラ ディスカバリー コーポレーション | 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用 |
SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
NZ567205A (en) | 2005-10-06 | 2010-05-28 | Sanofi Aventis | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
WO2007106391A1 (en) | 2006-03-10 | 2007-09-20 | Lymphosign Inc. | Compounds for modulating cell proliferation, compositions and methods related thereto |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
WO2008083158A2 (en) | 2006-12-26 | 2008-07-10 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
AU2009236256B9 (en) | 2008-04-14 | 2015-09-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
WO2010085968A1 (en) * | 2008-12-30 | 2010-08-05 | European Molecular Biology Laboratory (Embl) | Toluidine sulfonamides and their use as hif-inhibitors |
CA2758071C (en) * | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
US20120189670A1 (en) | 2009-09-14 | 2012-07-26 | Kirkpatrick D Lynn | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
CA2832100A1 (en) * | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
CA2895162C (en) | 2012-12-14 | 2021-03-09 | D. Lynn Kirkpatrick | Methods and compositions for inhibiting cnksr1 |
-
2013
- 2013-12-16 CA CA2895162A patent/CA2895162C/en active Active
- 2013-12-16 MX MX2015007608A patent/MX2015007608A/es active IP Right Grant
- 2013-12-16 EP EP13863280.7A patent/EP2931280B1/en active Active
- 2013-12-16 WO PCT/US2013/075505 patent/WO2014093988A2/en active Application Filing
- 2013-12-16 US US14/649,349 patent/US9340532B2/en active Active
- 2013-12-16 JP JP2015548050A patent/JP6357292B2/ja active Active
- 2013-12-16 AU AU2013358876A patent/AU2013358876B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016508969A5 (ja) | ||
JP2016513661A5 (ja) | ||
WO2017040993A4 (en) | Small molecule inhibitors of dyrk1a and uses thereof | |
JP2009541223A5 (ja) | ||
TW202014186A (zh) | 作為核轉運調節劑之化合物及其用途 | |
JP7319977B2 (ja) | チューブリン阻害剤 | |
JP2018510191A5 (ja) | ||
US20130281397A1 (en) | Treatment of diseases by epigenetic regulation | |
RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
CN104797565A (zh) | 新的苯磺酰胺噻唑化合物 | |
KR20140035493A (ko) | 중수소 농축된 4-하이드록시-5-메톡시-n,1-다이메틸-2-옥소-n-[(4-트리플루오로-메틸)페닐]-1,2-다이하이드로퀴놀린-3-카르복사미드 | |
Ozgur et al. | Heat shock protein 90 inhibitors in oncology | |
JP2014530243A (ja) | Arry−380の多形体、選択的herb2阻害剤、およびそれらを含有する薬学的組成物 | |
JP2015535247A5 (ja) | ||
RU2015147509A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы | |
JP2015515995A (ja) | キナーゼ阻害剤として有用な置換アミノキナゾリン | |
WO2021018032A1 (en) | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease | |
JP2019524738A (ja) | ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用 | |
Yin et al. | Development of novel chromeno [4, 3-c] pyrazol-4 (2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα | |
JP6357292B2 (ja) | Cnksr1を阻害するための方法及び組成物 | |
CA2464471A1 (en) | Method of treating depression with delta receptor agonist compounds | |
ITTO20100956A1 (it) | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi | |
EP3296294B1 (en) | Compound for treating or preventing breast cancer | |
BR112012022632A2 (pt) | Medicamento compreendendo agonista de ep4 | |
WO2014066967A1 (pt) | Compostos derivados de ingenol úteis no tratamento de câncer |